MERRIMACK PHARMACEUTICALS INC
MACK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MACK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2024.
Tracking 1 pipeline candidate · 1 clinical trial for MERRIMACK PHARMACEUTICALS INC.
Run MERRIMACK PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MERRIMACK PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
3234.6 months
D/E 0.10
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is MERRIMACK PHARMACEUTICALS INC's lead drug candidate?
MERRIMACK PHARMACEUTICALS INC's most advanced tracked candidate is onivyde (Approved) for metastatic adenocarcinoma of the pancreas.
What therapeutic areas does MERRIMACK PHARMACEUTICALS INC focus on?
MERRIMACK PHARMACEUTICALS INC develops therapies across Oncology, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.